Juno Therapeutics opened its new headquearters and research facility

| By | Cancer Drugs, Drug Development

Juno Therapeutics, Inc., a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, unveiled its new headquarters and research facility, located in the heart of South Lake Union in Seattle, USA.

“At Juno, our single focus is delivering on the promise of cell therapy. This is an exciting new frontier in medicine with the potential to change the way we treat cancer,” said Hans Bishop, Juno’s President and Chief Executive Officer. “Our new headquarters and research facility underscore our investment in this future and our commitment to deliver better treatments to our patients.”

Juno’s move to the headquarters and research facility comes during a momentous period for both the field of cell therapy and the company. The U.S. Food and Drug Administration approved the first chimeric antigen receptor (CAR) T therapy earlier this month, and Juno posted very encouraging data with JCAR017 in June. Juno believes data from the JCAR017 trial may support FDA approval for the treatment of aggressive non-Hodgkin Lymphoma as soon as 2018. Juno also possesses a deep pipeline of other product candidates focused on a number of cancers.

SOURCE: juno therapeutics
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.